Previs, RA, Bevis, KS, Huh, W, Tillmanns, T, Perry, L, Moore, K, Chapman, J, McClung, C, Kiet, T, Java, J, Chan, J, and Secord, AA. "A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy." Gynecologic oncology 132, no. 3 (March 2014): 531-536.
Angeles Alvarez Secord, MD
My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.
Education and Training
- Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
- M.D., University of Washington, 1994
- Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011
Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment.
Selected Grants and Awards
- Atezo NACT for Ovarian Cancer
- Lynparza Open Acess Olaparib
- GOG3015 Foundation Study ( Atezo Frontline)
- Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
- GOG3005-ABB VIE Protocol M13-694
- Quadra Study
- A Phase 2 Randomized Double-Blind Trial of Maintenance with Niraparib vs Placebo
- Apera ARP-407
- NCI National Clinical Trials Network U10 (Year 4)
- Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer
- Women with BRCA-mutated Advanced Stage Ovarian Cancer
- Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients
- Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer
- Tesaro Ovarian Cancer Practicum
- A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy
Secord, AA, Teoh, D, Jia, J, Nixon, AB, Grace, L, Adams, DJ, and Murphy, SK. "Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression." Int J Gynecol Cancer 24, no. 2 (February 2014): 218-225.
Ko, EM, Walter, P, Jackson, A, Clark, L, Franasiak, J, Bolac, C, Havrilesky, LJ, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, V. "Metformin is associated with improved survival in endometrial cancer." Gynecologic Oncology 132, no. 2 (February 1, 2014): 438-442.
Ko, EM, Walter, P, Jackson, A, Clark, L, Franasiak, J, Bolac, C, Havrilesky, LJ, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, V. "Metformin is associated with improved survival in endometrial cancer." Gynecol Oncol 132, no. 2 (February 2014): 438-442.
Krivak, TC, Lele, S, Richard, S, Secord, AA, Leath, CA, Brower, SL, Tian, C, and Moore, RG. "A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer." American Journal of Obstetrics and Gynecology 211, no. 1 (2014): 68.e1-68.e8.
Kokosis, G, Schmitz, R, Secord, AA, Havrilesky, LJ, Berchuck, A, Mantyh, CR, and Erdmann, D. "A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect." Gynakologe 47, no. 10 (January 1, 2014): 784-787.
Herzog, TJ, Monk, BJ, Rose, PG, Braly, P, Hines, JF, Bell, MC, Wenham, RM, Secord, AA, Roman, LD, Einstein, MH, Drake, RD, and Childs, BH. "A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube." Gynecologic Oncology 132, no. 3 (January 1, 2014): 517-525.
Previs, RA, Bevis, KS, Huh, W, Tillmanns, T, Perry, L, Moore, K, Chapman, J, McClung, C, Kiet, T, Java, J, Chan, J, and Secord, AA. "A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy." Gynecologic Oncology 132, no. 3 (January 1, 2014): 531-536.
Previs, RA, Edwards, JM, Secord, AA, Nucci, MR, Bentley, RC, and Hall, AHS. "Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: A case report." International Journal of Gynecological Pathology 33, no. 1 (January 1, 2014): 100-104.
Previs, RA, Edwards, JM, Secord, AA, Nucci, MR, Bentley, RC, and Hall, AHS. "Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: a case report." International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 33, no. 1 (January 2014): 100-104.